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Background: The disulfide-bonded region (DSR) of HIV-1 gp41 mediates association with gp120 and plays a role in
transmission of receptor-induced conformational changes in gp120 to gp41 that activate membrane fusion
function. In this study, forced viral evolution of a DSR mutant that sheds gp120 was employed to identify domains
within gp120-gp41 that are functionally linked to the glycoprotein association site.
Results: The HIV-1AD8 mutant, W596L/K601D, was serially passaged in U87.CD4.CCR5 cells until replication was
restored. Whereas the W596L mutation persisted throughout the cultures, a D601H pseudoreversion in the DSR
partially restored cell-free virus infectivity and virion gp120-gp41 association, with further improvements to cell-free
virus infectivity following a 2nd-site D674E mutation in the membrane-proximal external region (MPER) of gp41. In
an independent culture, D601H appeared with a deletion in V4 (Thr-394-Trp-395) and a D674N substitution in the
MPER, however this MPER mutation was inhibitory to W596L/K601H cell-free virus infectivity. While cell-free virus
infectivity was not fully restored for the revertant genotypes, their cell-to-cell transmission approached the levels
observed for WT. Interestingly, the functional boost associated with the addition of D674E to W596L/K601H was not
observed for cell-cell fusion where the cell-surface expressed glycoproteins function independently of virion
assembly. The W596L/K601H and W596L/K601H/D674E viruses exhibited greater sensitivity to neutralization by the
broadly reactive MPER directed monoclonal antibodies, 2F5 and 4E10, indicating that the reverting mutations
increase the availability of conserved neutralization epitopes in the MPER.
Conclusions: The data indicate for the first time that functional crosstalk between the DSR and MPER operates in
the context of assembled virions, with the Leu-596-His-601-Glu-674 combination optimizing viral spread via the
cell-to-cell route. Our data also indicate that changes in the gp120-gp41 association site may increase the exposure
of conserved MPER neutralization epitopes in virus.Background
The entry of HIV-1 into cells follows receptor binding by
the trimeric surface-exposed gp120 glycoprotein, which
activates the membrane fusion function of the trimeric
transmembrane glycoprotein, gp41. A globular head corre-
sponding to the gp120 trimer encompasses much of the
gp41 ectodomain [1,2], the association between gp120 and* Correspondence: apoumbourios@burnet.edu.au
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distribution, and reproduction in any mediumgp41 apparently trapping the glycoprotein complex in an
energetically strained or “metastable” state. The sequential
binding of gp120 to CD4 and then CCR5 or CXCR4
releases the trap, triggering the refolding of gp41 into a
6-helix bundle, which mediates membrane fusion and
viral entry (see [3,4]). Membrane fusion involves insertion
of the gp41 fusion peptide into the outer leaflet of the tar-
get membrane and the gp41 ectodomain adopting a
prehairpin intermediate conformation that bridges the
viral and cellular membranes [5-7]. 6-helix bundle forma-
tion brings together the N- and C-terminal membrane-tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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brane domain), apposing the associated viral and cellular
membranes for merger [8-10].
Evidence is accumulating to suggest that the associ-
ation site formed by the DSR of gp41 and the terminal
conserved regions 1 (C1) and 5 (C5) of gp120 [11-13]
act as a synapse for gp120-to-gp41 conformational sig-
naling (Figure 1A). For example, the simultaneous intro-
duction of Cys residues to the DSR and to C5 covalently
links the gp41-gp120 heterodimer, trapping it in a
fusion-inactive state with reduction of the intersubunit
disulfide required to activate membrane fusion [14,15].
Furthermore, mutations in the DSR can uncouple CD4-
gp120 binding from induction of the gp41 prehairpin
intermediate, and can block the initial lipid-mixing orFigure 1 Location and phenotype of WL/KD. (A) Location of WL/KD in t
the coordinates 3JWD [17] and 2QAD [20]. The gp120 core is colored blue,
magenta, respectively, gp41 binding site in green. gp41: the DSR (green) a
The N- and C-terminal helical segments of the MPER are colored purple an
sidechains of the aromatic/hydrophobic face of the MPER that inserts into the
gp41 association. Lysates of metabolically labeled WT, K601D, WL/KD, W596L o
culture supernatants (s) were immunoprecipitated with pooled IgG from HIV-1
reducing SDS-PAGE and phosphorimaging. (C) Cell-cell fusion activity. 293T effe
plasmids and then cocultured (18 h, 37°C) with CD4 plus CCR5-expressing BHK
units (RLU) of a representative experiment are shown. (D) 14-day replication kin
for RT activity and used to infect U87.CD4.CCR5 cells. The RT activity of the cult
mean RT activity ± standard deviation of triplicate samples is shown.hemifusion phase of the membrane fusion cascade. These
findings led to the proposal that the DSR acts as a sensor
of receptor-induced conformational changes in gp120
leading to the fusion activation of gp41 [16]. A 7-stranded
β-sandwich connecting the gp41-interactive C1 and C5
termini to the inner and outer domains of gp120 [17] also
plays a role in mediating association with gp41 [18] and in
regulating its activation state [19]. The β-sandwich links
together 3 structurally plastic layers that are remodelled
by CD4 engagement and coordinates the transmission of
this conformational change to the gp41 association site,
releasing gp41 from the metastable state.
The MPER, a highly conserved 23-residue Trp-rich se-
quence that connects the helical region 2 (HR2) of the
gp41 ectodomain to the transmembrane domain, playshe context of the gp120-gp41 ectodomain. gp120 was drawn using
CD4 binding site (CD4bs) and CCR5-binding site (CCR5bs) in cyan and
nd MPER were drawn using the coordinates 1IM7 [21] and 2PV6 [22].
d magenta respectively and the interhelical hinge in yellow. The
lipid phase of the membrane are indicated. FP: fusion peptide. (B) gp120-
r empty vector (No Env) transfected 293T cells (c) and corresponding
-infected persons and protein G-Sepharose. Proteins were analysed by
ctor cells were cotransfected with pCAG-T7 plus pcDNA3.1-AD8env
21 cells harboring a luciferase reporter plasmid. The mean relative light
etics in U87.CD4.CCR5 cells. Virus produced in 293T cells was normalised
ure supernatant was measured at days 3, 7, 10 and 14, postinfection. The
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[23-26]. This sequence has also been implicated in
modulating receptor-induced changes in the gp120-gp41
complex, since simultaneous mutations in the MPER
and the fusion-peptide proximal segment of gp41 block
CD4-induced shedding of gp120 from the gp120-gp41
complex and the initial, lipid mixing phase of the mem-
brane fusion cascade [27]. Spectroscopic studies of syn-
thetic MPER peptides indicate that this segment is likely
to reside in the lipid-polar head group interfacial region
of the envelope, lying roughly parallel to the membrane
plane, as a kinked helix comprising a tilted N-terminal
helix (res. 664–672) connected by a short hinge to a
C-terminal helix (res. 675–683) [22]. In current models,
the MPER is associated with the virion envelope at the
base of the metastable gp120-gp41 trimer, whereas fol-
lowing receptor activation, it associates with the fusion-
peptide proximal segment to form a clasp that stabilizes
the membrane-interactive end of the 6-helix bundle to
enable the initiation of membrane fusion [28-31]. Three
of the most broadly reactive neutralizing antibodies
(brNAb) against HIV-1 (2F5, 4E10 and Z13) bind to the
MPER and have been shown to contribute to protection
against viral challenge of passively immunized macaques
(see [23,24,32]). Thus the structure, function and im-
munogenicity of the MPER have been a focus of intense
study for many years, however the design of vaccines
that elicit 2F5- and 4E10-like antibodies has proven diffi-
cult (e.g. [33,34]).
The aim of this study was to identify determinants that
are functionally linked to the “activation synapse”. To this
end, we forced the evolution of a DSR mutant virus with
disrupted gp120 association, HIV-1AD8-W596L/K601D
(WL/KD), by sequential passage in U87.CD4.CCR5 cells.
A D601H pseudoreversion in the DSR operated in con-
junction with D674E in the MPER to improve gp120-gp41
association and to enable efficient viral spread in culture.
The revertant W596L/K601H (WL/KH) and W596L/
K61H/D674E (WL/KH/DE) viruses exhibited increased
sensitivity to the broadly neutralizing MPER-directed
MAbs 2F5 and 4E10. The data indicate that the MPER is
functionally linked to the association/activation synapse of
gp120-gp41 and suggest that changes in the gp120-gp41
association site may increase the exposure of conserved
MPER neutralization epitopes in virus.
Results
Phenotype of WL/KD
The gp120-gp41 association phenotype of the WL/KD
mutant was investigated by immunoprecipitation of biosyn-
thetically labelled Env glycoproteins expressed in 293T cells
[35]. The WL/KD mutation led to > 95% of total gp120
being sloughed into the culture supernatant (Figure 1B)
indicating a shedding phenotype that was more severe thanthose of the component single K601D and W596L
mutants. The loss of gp120-gp41 association for WL/KD
corresponded with the inhibition of cell-cell fusion function
in a luciferase reporter assay employing Env-293T effector
cells and CD4 and CCR5-expressing BHK21 targets
(Figure 1C). Consistent with these gp120-shedding and
fusion defects, WL/KD blocked HIV-1AD8 viral replication
in U87.CD4.CCR5 cells (Figure 1D).
Long-term culture of HIV-1AD8-WL/KD
Viruses derived from 2 independent HIV-1AD8 proviral
clones carrying WL/KD were subjected to long-term
culture in U87.CD4.CCR5 cells with serial passaging of
cell-free virus onto fresh cells every 10 days. Evidence
of replication was not observed for either clone, even after
50 days of culture (Figure 2A). The markedly diminished
gp120-anchoring ability of WL/KD gp41 was assumed to
have blocked viral entry and therefore reverse transcription,
which is required for the generation of suppressor muta-
tions. Mutant WL/KD HIV-1 particles were therefore
pseudotyped with vesicular stomatitis virus glycoprotein G
(VSV G) in trans in order to initiate HIV-1 envelope glyco-
protein (Env)-independent infection via the endosomal
pathway. Twenty-four h after infection, the U87.CD4.CCR5
cells were extensively washed and trypsinized to remove
residual adsorbed virus prior to further culture for 10 days.
The sequential passaging of the resultant cell-free virus
in U87.CD4.CCR5 cells led to restored infectivity after 47
and 30 days in WL/KD cultures 1 and 2 (WLKD-1 and
WLKD-2), respectively (Figure 2B).
The env region was PCR-amplified from genomic
DNA isolated at days 10, 20, 30, 40 and 50, the PCR prod-
ucts were cloned into pΔKAD8env, and the entire env re-
gion was sequenced. WLKD-1. A D601H pseudoreversion
emerged at day 10 (2/6 clones, WL/KH) prior to the
appearance of D674E in the MPER at day 20, which
persisted throughout the culture period. The genotypes
observed over the 50-day culture period included WL/KH
(9/35 clones), W596L/K601H/D674E (WL/KH/DE [10/35
clones]), L85M/W596L/K601H/D674E (LM/WL/KH/
DE [6/35 clones]), W596L/K601H/D674G (WL/KH/DG
[4/35 clones]), L85M/W596L/K601H (LM/WL/KH [1/35
clones]), and W596L/K601H/D674N (WL/KH/DN [1/35
clones]) (Figure 2C). WLKD-2. At day 10, 3/6 clones
contained WL/KH, while 3 others contained the Thr-394-
Trp-395 deletion in V4 (ΔTW), together with W596L and
D601H in the DSR, and D674N in the MPER (ΔTW/WL/
KH/DN). The ΔTW/WL/KH/DN genotype persisted to
day 30 but at days 40 and 50, the dominant genotype was
WL/KH/DN (13/18 clones) (Figure 2C). The W596L mu-
tation was retained in 70/71 env clones obtained from the
WLKD-1 and WLKD-2 cultures indicating a strong selec-
tion pressure to maintain Leu at 596. The K601H and
D674E mutations were not observed in env clones
Figure 2 Long-term culture of W596L/K601D virus. (A) Wild type and W596L/K601D-mutated HIV-1AD8 virus stocks produced by transfected
293T cells were normalized according to RT activity and used to infect U87.CD4.CCR5 cells. The cell-free virus obtained at day 10 was filtered
through a 0.45 μm nitrocellulose filter, normalized according to RT activity and used to infect fresh U87.CD4.CCR5 cells. Viruses were subjected to
5 sequential passages in total. (B) Infection of U87.CD4.CCR5 cells was initiated with VSV G-pseudotyped WT and W596L/K601D mutant viruses.
The cells were trypsinized 24-h later to remove residually adsorbed viruses. The passaging procedure described in A was then followed. The
results shown represent the mean RT activity ± standard deviation of triplicate samples. (C) Reversion pathways in WLKD-1 and WLKD-2 cultures.
The env region was PCR amplified from proviral DNA isolated at days 10, 20, 30, 40 and 50, cloned into pΔKAD8env and sequenced. Upper case
lettering connected by a bold horizontal line denotes a major evolutionary pathway, while lower case lettering connected via thin horizontal
lines denotes a minor pathway. Lower case lettering only: low-frequency genotypes arising at the specified days.
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D674N was observed in 1 clone (data not shown).
Infectivity of WL/KD revertants
The dominant genotypes were reconstructed in the context
of the pAD8 proviral clone. In the case of WLKD-1, cell-
free virus-initiated replication in U87.CD4.CCR5 cells was
partially restored by D601H in the DSR (WL/KH) and wasoptimised further by D674E in the MPER (WL/KH/DE)
(Figure 3A). The addition of L85M to WL/KH/DE did
not improve replication any further. Interestingly, the
WL/KH/DG combination was replication-incompetent.
Gly-674 can arise via an A-to-G mutation in the 2nd pos-
ition of the Asp and Glu codons but in a WL/KH context
appears to be an evolutionary dead-end. These data suggest
that D601H and D674E can act synergistically to suppress
Figure 3 Replication of representative WLKD-1 (A) and WLKD-2 (B) clones in U87.CD4.CCR5 cells. Viruses produced in 293T cells were
normalized according to RT activity and used to infect U87.CD4.CCR5 cells. Reverse transcriptase activity in culture supernatants was measured at
days 3, 7, 10 and 14. The mean RT activity ± standard deviation of triplicate samples is shown. (C) Single-cycle infectivity was determined in U87.
CD4.CCR5 cells infected with Env-pseudotyped luciferase reporter viruses at 48-h postinfection. Luciferase activity was normalized against the RT
activity present in each virus inoculum. The mean RLU ± standard errors of 3 independent assays are presented here. **, P < 0.01, unpaired t test
assuming unequal variances. (D) Serial 10-fold dilutions of Env-pseudotyped luciferase reporter viruses were added to U87.CD4.CCR5 target cells
and luciferase activity determined 48 h later. The mean RLU ± standard deviations from a representative experiment are presented.
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improvements in replication competence were observed
with WL/KH/DN, ΔTW/WL/KH/DN and WL/KH, re-
spectively (Figure 3B). Thus D674N is inhibitory to cell-free
virus initiated replication in the context of WL/KH with
ΔTW partially relieving this inhibition. The G145E V1
mutation observed at days 30–40 did not confer a replica-
tion advantage to WL/KH/DN. Interestingly, the replication
competence of WLKD-2 genotypes were inferior to those
derived from the WLKD-1 culture even though revertant
virus emerged in the WLKD-2 culture first, suggesting
that additional mechanisms of reversion were operating in
this culture.
The infectivity associated with revertant genotypes
was further examined in a single cycle infectivity assay
employing Env-pseudotyped luciferase reporter viruses.
The infectivity of WL/KD for U87.CD4.CCR5 cellular
targets was reduced by ~ 2.5log10 with respect to WT
(Figure 3C). The D601H pseudoreversion in WL/KH
increased this infectivity by ~10-fold while the addition of
D674E led to a further 2-fold improvement, but the entry
competence of WL/KH/DE remained 20-fold lower than
WT. The addition of D674G to WL/KH (WL/KH/DG)
markedly suppressed viral entry consistent with theobserved lack of replication. The alternate MPER mutation,
D674N, was inhibitory on the WL/KH background, consist-
ent with the relative replicative capacity of WL/KH/DN
and WL/KH, while the addition of ΔTW to WL/KH/DN
did not improve single-cycle entry competence any further.
We next determined if the modulation of infectivity by
D674E, D674N and D674G occurred via a functional
link to Leu-596 and His-601 or whether it could be
explained by a generalized enhancement or inhibition in
Env function. Figure 3D indicates that the D674 muta-
tions did not alter the infectivity of Env-pseudotyped lu-
ciferase reporter virus when introduced to the WT
background, indicating a specific functional interaction
between Leu-596, His-601 in the DSR and position 674
in the MPER.
Cell-cell spread of revertant viruses
The functional advantages conferred by D601H and
D674E were less obvious in the single cycle infectivity
assay when compared to 14-day replication experiments
(compare Figure 3A, B and C). This apparent discrepancy
may be explained by the fact that only a single cycle of in-
fection mediated by cell-free virus occurs in the reporter
assay, whereas multiple rounds of infection mediated by
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cation assay [36,37]. We therefore inoculated U87.CD4.
CCR5 cells with HIV-1-VSV G pseudotyped particles, rea-
soning that the highly fusogenic nature of VSV G will
normalize the cellular entry of cell-free WT and revertant
viruses in the first 24 hours of infection, thereby enabling
an assessment of virus production following multiple
rounds of cell-cell and cell-free viral transmission. At 24-h
postinfection, the cells were trypsinized to remove residual
surface-adsorbed virus, replated and then cultured for a
further 10 days. Virus production was elevated for WL/
KH/DE with respect to WT at day 7 and approached WT
levels at day 10, whereas WL/KH, WL/KH/DN and
ΔTW/WL/KH/DN replication was almost identical to
WT over the 10-day culture (Figure 4A). A low level
of reverse transcriptase (RT) activity was observed for
WL/KD, which is likely due to a combination of virus pro-
duction by cells infected by VSV G-pseudotypes in the ini-
tial 24 h plus low-level cell-cell spread. The results were
confirmed in an experiment employing smaller inocula
(20,000 cpm RT activity-equivalents of VSV G-HIV-1
pseudotypes) but virus production was delayed to day 10
in this case (Figure 4B). Notably, the presence of D674N
was not inhibitory to replication when combined with
WL/KH in this infection system. We found that viral
spread in VSV G-HIV-1 pseudotype initiated cultures was
blocked by the C34 fusion inhibitor peptide, consistent
with viral spread being HIV-1 Env dependent (Figure 4C).Figure 4 Spread of cell-associated virus. U87.CD4.CCR5 cells were inocu
cpm of RT activity per inoculum] and then trypsinized 24-h later to remove
a further 10 days. The results shown represent the mean RT activity ± stand
peptide was maintained in the culture following the trypsinization step. Eff
free (D) and cell-associated (E) virus in 10-day U87.CD4.CCR5 cultures. The
duplicate samples obtained from the cultures.These data suggest that the D601H pseudoreversion and
2nd (and 3rd) site mutations optimise viral spread medi-
ated by cell-associated virus.
We next determined whether D674E and D674N on a
WT HIV-1AD8 background had any effect on cell-free
or cell-associated viral transmission in 10-day U87.CD4.
CCR5 cultures. The cells were inoculated with 50,000 cpm
RT-equivalents of non-pseudotyped (Figure 4D) or VSV
G-pseudotyped (Figure 4E) virions. At 24-h postinfection,
the cells inoculated with VSV G pseudotypes were tryp-
sinized and replated. The virus content of the culture su-
pernatants at days 4, 7 and 10 postinfection was quantified
by p24 ELISA. The data show that D674E and D674N did
not affect cell-free or cell-cell viral transmission (Figure 4D
and E, respectively). By contrast, WL/KD blocked virus
transmission in both cases. These data further support the
conclusion that position 674 in the MPER is specifically
linked to Leu-596 and His-601 in the DSR.
Glycoprotein expression and subunit association
The synthesis and processing of the cloned Env glyco-
proteins were examined by western blot. The gp120-
specific polyclonal antibody, DV-012, (Figure 5A, upper)
revealed that similar levels of gp160 were expressed for
all clones and that cell-associated gp120 was present for
WT and His-601-containing clones. Consistent with the
shedding defect seen previously (Figure 1B), gp120 was
largely absent for WL/KD. The monoclonal antibodylated with VSV G-pseudotyped HIV-1 particles [50,000 (A) or 20,000 (B)
residual adsorbed virus. The cells were then replated and cultured for
ard deviation of triplicate samples. (C) As for B except that 1 μM C34
ects of D674E and D674N mutations on viral spread initiated by cell-
results shown represent the mean p24 content ± standard deviation of
Figure 5 Biochemical analysis of selected revertant clones.
(A) Western blotting. At 48-h posttransfection, pΔKADenv–transfected
293T cells were lysed and subjected to reducing SDS-PAGE followed
by western blotting with DV-012 to gp120 (upper panel) and mAb C8
to gp41 (lower panel). (B) gp120-gp41 association was determined as
for Figure 1B. gp120-shedding index was calculated according to the
formula: ([mutant gp120]supernatant x [WT gp120]cell)/([mutant gp120]
cell x [WT gp120]supernatant) [12]. (C) Characterization of virions produced
by pAD8 infectious clones. Pelleted HIV-1 virions were analysed by
Western blotting using DV-012 (upper panel) and pooled IgG from HIV-
1-infected persons (lower panel). gp120 and p24 band intensities were
determined using a Licor Odyssey scanner.
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plasmic domain of gp41 [38], revealed similar levels of
gp160 and gp41 expression for the Env constructs exam-
ined (Figure 5A, lower). Interestingly, the presence of
the WL/KD mutation in gp41 resulted in a distinct gly-
cosylation pattern relative to the other clones, suggesting a
subtly different structure. The gp120 anchoring ability of
the cell-surface expressed revertant Env proteins was ana-
lyzed by immunoprecipitation of pulse-chase biosyntheti-
cally labelled Env transfected 293T cells. Figure 5B again
confirms the gp120 shedding defect of WL/KD and indi-
cates that the subsequent D601H mutation, present in the
WL/KH clone was sufficient to partially restore gp120 as-
sociation levels with no further improvements to associ-
ation following the addition of 2nd and 3rd site mutations.
By contrast, Western blot analysis of viruses pelleted from
the supernatants of 293T cells transfected with pAD8 pro-
viral clones revealed gp120 shedding phenotypes for the
revertants (Figure 5C). These data indicate that stable
gp120-gp41 association is not conferred by the reverting
mutations in a cell-free virion context. The apparent dis-
crepancy between cellular and virion Env could be related
to the fact that cellular Env was analysed 5 h post synthe-
sis whereas virions were analysed at 48 h posttransfection.
It may be that a subtly unstable gp120-gp41 complex be-
comes more evident over time. Interactions between
the cytoplasmic tail of gp41 and the MA domain of Gag in
the context of cell free virions have been found to impose
structural and functional constraints on the Env
ectodomain [39-42]. These data suggest an alternative sce-
nario where WL/KH-containing revertant Envs attain ap-
parently WT gp120-gp41 stability when expressed in the
absence of other viral proteins, whereas the corresponding
virion-associated glycoprotein complexes are less stable in
an Env conformation that is modulated by internal Env-
Gag interactions.
Examination of the 601–674 functional linkage in cell-cell
fusion
We next examined the membrane fusion activities of se-
lected revertant Env sequences in a cell-to-cell fusion
assay. In this context, Env is expressed in the absence of
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conformational constraints that may be imposed by
matrix-gp41 cytoplasmic tail interactions present in
virus [39-42]. The assay was conducted at limiting Env
concentrations (0.25 μg pΔKADenv) to enable detection
of subtle changes in fusion function. Consistent with the
cell-free virus infectivity data, WL/KD blocked cell-cell fu-
sion, WL/KH exhibited partially restored fusion function
and D674N and D674G mutations were inhibitory in a
WL/KH context (Figure 6). However, in contrast to the in-
fectivity data, D674E did not enhance fusogenicity when
added to WL/KH. These data suggest that the functional
interaction between Leu-596, His-601 and Glu-674 largely
operates in the context of assembled virions transmitted via
the cell-cell route and the conformational constraints im-
posed by Gag-gp41 cytoplasmic tail interactions [39-42].
Neutralization sensitivity of WL/KH and WL/KH/DE
mutants
To determine whether WL/KH and WL/KH/DE are asso-
ciated with structural changes in gp41, neutralizing agents
were used to probe functional virion-associated gp120-
gp41 complexes. Virus stocks, produced by transfecting
293T cells with pAD8 infectious clones, were adjusted to
produce ~ 1.5 × 106 RLU following 48 h of infection of
TZM-bl cells. The viruses were then incubated with theFigure 6 Cell-cell fusion activities of revertant Envs. 293T
effectors (cotransfected with pΔKAD8env plus pCAG-T7) were
cocultured with BHK-21 targets cotransfected with pT4luc and
pcCCR5 vectors for 18 h and then lysed and assayed for luciferase
activity. The data presented here are the means ± standard errors of
3 independent assays. *, P < 0.05, unpaired t test assuming
unequal variances.neutralizing agents for 1 h prior to infection of naïve
TZM-bl cells. In the case of the CCR5 antagonist
maraviroc, target cells were pretreated with the inhibitor
for 1 h prior to infection. The CD4 binding site brNAb,
IgGb12, and the CCR5 antagonist, maraviroc, neutralized
WT, WL/KH and WL/KH/DE to similar extents (the
maraviroc IC50 and IC90 values for WT were not signifi-
cantly different to those obtained with the mutants) indi-
cating that gp120-CD4-CCR5 interactions had not been
affected by the mutations in gp41 (Figure 7). Small, but
significant ~ 0.5log10-decreases in C34 IC50, a gp41 HR2
peptide analog that binds to the helical region 1 (HR1)
coiled coil in a fusion intermediate conformation of gp41
[6,43,44], were observed for the revertants in relation to
the WT (P < 0.05, WL/KH and WL/KH/DE versus WT;
2-tailed t test, unequal variances). Notably, WL/KH and
WL/KH/DE exhibited markedly greater sensitivity to
neutralization by the MPER-specific brNAbs 2F5 and
4E10 when compared to the WT. These data are consist-
ent with structural changes in the gp120-gp41 complex
that increase the availability of neutralization targets in the
MPER of gp41.
Discussion
The forced evolution of WL/KD mutant viruses with se-
verely disrupted gp120-gp41 association led to the emer-
gence of replication-competent revertants containing a
D601H pseudoreversion in the DSR plus D674E or
D674N 2nd site mutations in the MPER. In a second
culture, revertant clones contained the ΔT394-W395 de-
letion in V4 in addition to D601H and D674N. The WL/
KH and WL/KH/DE viruses exhibited greater sensitivity
to the brNAbs, 2F5 and 4E10, indicating that the restor-
ation of function was associated with structural changes
in Env that increase the accessibility of neutralization
epitopes within the MPER. Our data reveal a functional
linkage between the DSR and MPER of gp41 and point
to a novel approach for improving the accessibility of
conserved neutralization epitopes within the MPER in a
virion context.
The severe shedding phenotype of WL/KD is likely to
have resulted from the combined effects of decreased
hydrophobic sidechain bulk and an additional negative
charge in the contact site, that destabilizes gp120-gp41
association. Phenotypic analysis of the revertant geno-
types indicated that D601H is a key evolutionary step
that partially restores gp120-gp41 association. Histidine
at 601 introduces an imidazole moiety into the associ-
ation site, which would partially compensate for the loss
of the indole ring of Trp-596 and removes the negative
charge contributed by Asp-601. Interestingly, Leu-596
was maintained in both long-term cultures, indicating
that the smaller hydrophobic sidechain is preferred at
this position when His is present at 601. While His is
Figure 7 Sensitivity of revertants to neutralizing agents. The
TZM-bl cells were incubated with virus-inhibitor complexes for 2
days prior to lysis and then assayed for luciferase activity. For the
maraviroc experiment, target cells were incubated in the presence
of the inhibitor for 1 h prior to inoculation. Neutralizing activities are
reported as the average percent maximal luciferase activity. The data
presented here are the means ± standard errors; n = 2 for IgGb12,
2F5 and 4E10; n = 3 for C34 and maraviroc.
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ring may become protonated if it is proximal to acidic
residues. In this case, the D601H mutation would also
restore positive charge to position 601, which may also
lend stability to the gp120-gp41 association site. The
combination of His-601 with D674E led to improved
single-cycle and multi-cycle cell-free virus-initiated in-
fectivity without detectable further improvement in
gp120-gp41 association. The MPER mutation therefore
appears to act at the level of virus entry. Highly mutable
viruses, such as HIV-1 have the capacity to overcome fit-
ness defects via multiple evolutionary pathways. It was
therefore notable that we found a functional link be-
tween positions 601 and 674 of gp41 in parallel cultures,
indicating a reproducible genetic link between the DSR
and MPER. However, we cannot rule out the possibility
that additional solutions to restore the gp120-gp41 inter-
action would be revealed with more independent evolu-
tion cultures of WL/KD.
Nuclear magnetic resonance studies of synthetic
MPER peptides suggest that in membranes, the MPER is
a metastable L-shaped structure comprised of N- and C-
terminal helical segments that are connected via a hinge
composed of Phe-673, which is buried in the lipid phase,
and a polar residue at position 674, which is solvent-
exposed (Figure 8) (PDB entry, 2PV6 [22]. The C-
terminal helix is likely to interact with the transmem-
brane domain and cholesterol in the lipid phase via the
Leu-679-Trp-Tyr-Ile-Lys cholesterol recruitment motif
[45-48], while the N-terminal helix represents a more
flexible segment that might be in a metastable state and
contains 3 Trp residues that are critical for membrane
fusion [25]. Molecular modeling predicts that the ori-
ginal Asp side chain at position 674 will hydrogen bond
via Oδ1 with the backbone amides of Asn-677 and Ile-
675 in 17 of 17 MPER conformers (Figure 8A), thereby
conferring rigidity to the interhelical hinge. By contrast,
an additional methyl group within the Glu-674 sidechain
moves the terminal carboxylate out of hydrogen bonding
range in 15/17 conformers, consistent with hinge flexi-
bility (Figure 8B). The boost to the infectivity of WL/KH
cell-free virus upon addition of D674E may therefore be
related to increased MPER flexibility. Interestingly, the
addition of D674E to W596L/K601H only marginally
improved gp120-association for cell-free virions whereas
Figure 8 Amino acid changes at position 674 modeled on the
dodecylphosphocholine-associated MPER peptide (PDB entry
2PV6). The Asp-674 (A), Glu-674 (B), and Asn-674 (C) models were
produced with Swiss Model and drawn with Pymol. The N- and
C-terminal helical segments are shown in purple and magenta
respectively, while Phe-673 that forms part of the hinge region is
in yellow. The aromatic layer and Ile-675, which are associated with
the hydrophobic phase of the lipid are indicated. The N-terminus
is to the left.
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may be that increased MPER hinge flexibility due to
D674E relieves or corrects a structural constraint on
WL/KH-containing Env to enable stronger gp120-gp41
association within the virion glycoprotein complex,thereby enhancing entry function. It is also possible that
D674E directly enhances an MPER-related function in
virus-cell fusion [25,49]. For example, greater flexibility
in the MPER may facilitate its relocation from the lipid-
polar head group interfacial region of the envelope for
interaction with the fusion peptide-proximal segment dur-
ing terminal clasp formation at the membrane-proximal
end of the 6-helix bundle during the initiation of fusion
[28,30]. Alternatively, the membrane perturbing properties
of the MPER may be enhanced by D674E [26,50-52].
Mutational studies have indicated that the DSR is asso-
ciated with the C1 and C5 regions of gp120 [11-13,35],
which project from the base of gp120 [17] (Figure 1A).
The modeling of these projections in a trimeric context
suggests that they will form a layer that encases the DSR
[16], thereby occluding it from antibody recognition
[53,54]. On the other hand, the MPER is believed to oc-
cupy a spatially distinct location at the base of the gp41
trimer, partially embedded in the envelope and in certain
HIV-1 strains, available for antibody binding [53-55]. The
MPER-DSR functional linkage is therefore likely to oper-
ate via an allosteric mechanism that involves other struc-
tural elements of the ectodomain. The HR1 of gp41 is
implicated as one such element by the finding that T569A
(HR1) and I675V (MPER) polymorphisms synergize in
conferring a neutralization sensitive Env conformation
[56]. Furthermore, fusion inhibitor- and neutralizing
antibody-driven viral evolution studies have suggested
functional linkages between HR1, the receptor and
coreceptor binding sites of gp120, and HR2 [57,58]. We
did not observe significant changes in the sensitivity of
cell-free viruses to the CD4-binding site-directed brNAb
b12 or to maraviroc, suggesting that alterations to the re-
ceptor and coreceptor binding sites did not contribute to
the mechanism of reversion. However, a small (0.5log10)
but significant increase in C34 sensitivity was observed for
WL/KH and WL/KH/DE viruses. Subtle alterations to the
function of HR1 during fusion, such as prehairpin coiled
coil formation, may accompany the WL/KH and WL/KH/
DE changes.
In contrast to the data obtained with cell-free virions,
replication levels at (WL/KH, WL/KH/DN, ΔTW/WL/
KH/DN) or better (WL/KH/DE) than those of WT were
achieved by the revertants when infections were initiated
with VSV G pseudotyped viruses. In this latter system,
the initial infection rounds will be largely mediated by
the highly fusogenic VSV G present in the viral envelope
thereby normalizing WT and mutant virus infectivity,
while subsequent infection rounds will be mediated by
gp120-gp41 present on virions transmitted directly from
cell to cell via virological synapses in addition to nascent
cell-free virions. Direct cell-cell viral transmission has
been calculated to be at least 8-times more efficient than
cell-free viral spread and is believed to be due to higher
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within virological synapses [37]. It may be that in the
case of cell-free virions, which encounter receptors fol-
lowing solution-phase diffusion, gp120 is shed from
unstable WL/KH, WL/KH/DE and WL/KH/DN gp120-
gp41 complexes during the lag time between budding
and attachment, thereby decreasing infectivity over time.
Consistent with this idea, gp120-gp41 association was
observed to be relatively weak in cell-free revertant vi-
rions. By contrast, in directed viral transmission across
virological synapses, virion budding, receptor binding,
virion maturation and entry appear to be closely linked
and to occur over short timeframes [36,59,60], which
may limit the loss of gp120 from virions prior to recep-
tor encounter. An alternative scenario is suggested by
the recent work of Dale et al. [59] who found that
in cell-cell viral transmission, receptor attachment is me-
diated by immature virions, and Env activation for fu-
sion occurs later following viral maturation in the
endosome. This contrasts cell-free virus infection where
receptor binding is largely mediated by mature virions.
It may be that the reverting mutations act optimally
in the context of viral gp120-gp41 complexes that are
initially maintained in an inactive form, through interac-
tions between the gp41 cytoplasmic domain and imma-
ture Gag [40,42], prior to receptor engagement and
activation for fusion. Overall, these data suggest that the
cell-cell mode of viral spread plays the key role in the
mechanism of reversion. This idea is consistent with
the finding that the WL/KH/DN and ΔTW/WL/KH/DN
env genotypes coexist with WL/KH in the WLKD-2 cul-
ture even though the former exhibited lower cell-free
virus infectivity. It is interesting that the boosts to infect-
ivity associated with the addition of D674E to W596L/
K601H did not correlate with enhanced cell-cell fusion
activity, where the cell-surface expressed glycoproteins
function independently of other virion components.
These data are consistent with a Leu-596-His-601-Glu-
674 functional interaction that is dependent on virion
assembly and the structural constraints imposed on the
Env ectodomain, including the MPER, by Gag-gp41
cytoplasmic tail interactions [39-42].
The WL/KH (and WL/KH/DE) mutations were associ-
ated with increased sensitivity to the 2F5 and 4E10 MPER-
directed brNAbs, indicating a structural change in Env
that increases MPER accessibility. Two neutralization
mechanisms have been proposed for 2F5 and 4E10: i) dir-
ect interaction with the MPER in neutralization-sensitive
viral strains; ii) Env-receptor interaction-triggered MPER
accessibility to brNAb in resistant strains [55]. We have
found that the macrophage-adapted AD8 strain is rela-
tively resistant to these brNAbs, suggesting that the MPER
is sterically occluded in the WT viral AD8 Env complex.
The WL/KH gp120-gp41 association site mutation maylead to a more open Env structure, enabling better epitope
access for 2F5 and 4E10. Alternatively or additionally,
WL/KH may be associated with structural change in
the MPER itself, with increased MPER flexibility and/or
altered membrane interactions facilitating paratope-
mediated extraction of the 2F5 and 4E10 epitopes from
the envelope. These proposed changes to the MPER may
be present in cell-free virions or could occur during the
virus-cell fusion process [55].
MPER-specific brNAbs are of particular interest to the
HIV-1 vaccine field due to the conserved nature of their
epitopes and their neutralization breadth [23,61-64]. Bio-
physical and structural studies have indicated that
membrane-anchored MPER conformations are optimally
bound by 2F5 and 4E10-like brNAbs [65], but the goal of
developing a vaccine that presents the MPER in a lipid en-
vironment and produces high-titre 2F5- and 4E10-like anti-
bodies with broad neutralization properties has not yet
been realized [34,66-69]. This may in part be due to poor
mimicry of MPER conformations in artificial lipopeptide
immunogens that are required to elicit the appropriate
antibody ancestor and to then drive a high degree of som-
atic mutation that gives rise to mature brNAbs, such as
4E10 [70,71]. Our finding that WL/KH in the gp120-gp41
association site can sensitize HIV-1 to 2F5 and 4E10 sug-
gests that the MPER is more accessible to these brNAbs. It
is plausible that incorporation of WL/KH (or WL/KH/DE)
into a HIV-like particle immunogen may increase the ex-
posure of MPER epitopes in a quasi-native context and in
conformations that promote the production of 2F5/4E10-
like specificities. Such an approach would also enable modi-
fications to gp120, itself a major target of brNAbs and
apparently protective vaccine responses [72-74], to improve
its association with gp41 and its immunogenicity in regard
to brNAbs. We consider that the approach used here
may help researchers to identify mutations that would in-
crease the stability and gp120 retention of Env trimer-
based immunogens.
We previously reported that the contributions of
Trp-596 and Lys-601 to gp120-gp41 association and
membrane fusion are influenced by sequence changes
in V1, V2, and V3 [35], which are predominantly asso-
ciated with the evolution of neutralization resistance
[75-81], as well as coreceptor preference and cellular
tropism [82-85]. Thus the gp120-gp41 association site
appears structurally and functionally adaptable, perhaps
to maintain glycoprotein function during gp120-gp41
evolution. The observation here of functional crosstalk
between the DSR and MPER implies that the structural
adaptation of the gp120-gp41 synapse in order to cope
with the evolution of other glycoprotein domains is also
linked to changes in MPER structure that alters the
ability of conserved neutralization epitopes therein to
be bound by antibody.
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We have found, by using a forced virus evolution ap-
proach, evidence for functional crosstalk between the
gp120-gp41 association site and the MPER. Our data indi-
cate that looser gp120-gp41 association due to the WL/
KH mutation within the DSR is linked to enhanced
neutralization by brNAbs directed to the MPER. Our work
points to a new approach for improving the accessibility
of conserved MPER neutralization epitopes in virion-
based immunogens.
Methods
Env expression vectors and proviral clones
The CMV promoter-driven HIV-1AD8 Env expression vec-
tor, pCDNA3.1-AD8env, is described elsewhere [35].
pΔKAD8env was derived by religation of the end-filled
HindIII and EcoRI sites of pCDNA3.1-AD8env. Mutants
of the pAD8 infectious clone (obtained from K. Peden
[86]) were prepared by transferring the EcoRI-BspMI env-
containing fragment from pCDNA3.1-AD8env vectors
into pAD8. In vitro mutagenesis of the gp41 region was
carried out using the Quikchange protocol (Stratagene).
Infection of U87.CD4.CCR5 cells
Virus stocks were prepared by transfecting 293T cell
monolayers with pAD8 infectious clones using Fugene 6
or Fugene HD (Roche). Virus-containing transfection su-
pernatants were normalized according to RT activity, and
then used to infect U87.CD4.CCR5 astroglioma cells (from
H. Deng and D. Littman [87], NIH AIDS Research and
Reference Reagent Program) in 25 cm2 culture flasks. The
supernatants were assayed for RT activity [88] or p24 con-
tent (NCI p24 antigen capture ELISA) at various time
points. To assess the transmission of cell-associated vi-
ruses, HIV-1 particles were pseudotyped with VSV G by
cotransfection of 293T cells with pAD8 and pHEF-VSV G
(from Dr. L.-J. Chang [89] NIH AIDS Research and Refer-
ence Reagent Program). U87.CD4.CCR5 cells in 25 cm2
culture flasks were inoculated with the HIV-VSV G
pseudotypes, and then, at 24-h postinfection, trypsinized
to remove surface-adsorbed virions. The cells were
replated and then cultured for 10 days. The culture super-
natants were assayed for RTactivity or p24 content at vari-
ous time points. For long-term cultures of viral mutants,
the day-10 cell-free culture supernatants were filtered
(0.45 μm pore size) and normalized according to RT activ-
ity prior to the next passage (5 passages in total). Genomic
DNA was extracted from infected cells using Qiagen
DNeasy Blood and Tissue kit. The viral DNA fragment
encompassed by nucleotides 5954–9096 (HIV-1HXB2R
numbering convention) was PCR-amplified using Expand
HiFi (Roche) and the primers, 5’-GGCTTAGGCATC
TCCTATGGCAGGAAGAA (Env1A) and 5’-TAGCCC
TTCCAGTCCCCCCTTTTCTTTTA (Env1M) [90]. Theamplified sequences were ligated into pΔKAD8env (KpnI-
XbaI) and the entire env open reading frame sequenced
using ABI BigDye terminator v3.1.
Single cycle infectivity assays
Single cycle infectivity assays were conducted as described
[27]. Env-pseudotyped luciferase reporter viruses were
produced by cotransfecting 293T cells with pΔKAD8env
plus the luciferase reporter virus vector, pNL4.3.Luc.R-E-
(NIH AIDS Research and Reference Reagent Program,
from N. Landau [91]), using Fugene HD. The infectivity of
pseudotyped viruses was determined in U87.CD4.CCR5
cells using the Promega luciferase assay system at 48 h
postinfection.
Western blotting
Twenty four h after transfection with pΔKAD8env vec-
tors, 293T cells were lysed for 10 min on ice in PBS
containing 1% Triton X-100, 0.02% sodium azide, 1 mM
EDTA. The lysates were clarified by centrifugation for
10 min at 10,000 ×g at 4°C prior to SDS-PAGE under re-
ducing conditions. The proteins were transferred to
nitrocellulose and blotted with antibodies C8 to gp41
[38] and DV-012 to gp120 [92] (from G. Lewis and M.
Phelan, respectively, NIH AIDS Research and Reference
Reagent Program). The immunoblots were developed
with Alexa Fluor 680-conjugated goat anti-mouse or
donkey anti-sheep immunoglobulin (Invitrogen) and
scanned in a LI-COR Odyssey infrared imager. For vir-
ion analysis, supernatants from pAD8-transfected 293T
cells were centrifuged over 1.5 ml 25% w/v sucrose/PBS
cushions (Beckman SW41 Ti rotor, 25,000 rpm, 2.5 h, 4°C)
prior to reducing SDS-PAGE and western blotting with
DV-012 to detect gp120 and pooled IgG from HIV-1-
infected individuals to detect Gag proteins.
Biosynthetic labeling and immunoprecipitation
293T cells were transfected with pΔKAD8env vectors.
At 24-h posttransfection, the cells were incubated for
30 min in cysteine and methionine-deficient medium
(MP Biomedicals), and then labeled for 45 min with 150
μCi Tran-35S-label (MP Biomedicals). The cells were
washed and then chased in complete medium for 5 h
prior to lysis. Cell lysates and clarified culture superna-
tants were immunoprecipitated with pooled IgG from
HIV-1-infected persons and protein G Sepharose
and subjected to SDS-PAGE in the presence of β-
mercaptoethanol. The labeled proteins were visualized
by scanning in a Fuji phosphorimager.
Luciferase reporter assay of cell-cell fusion
Cell-cell fusion assays were conducted as previously de-
scribed [27]. Briefly, 293T cells were cotransfected with
pΔKAD8env and the bacteriophage T7 RNA polymerase
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were cotransfected with pc.CCR5 (AIDS Research and
Reference Reagent Program from N. Landau [94]) and
pT4luc, a bicistronic vector that expresses human CD4
from a CMV promoter and firefly luciferase from a T7
promoter [13]. At 24 h posttransfection, targets and ef-
fectors were cocultured in triplicate in a 96-well plate
(18 h, 37°C) and then assayed for luciferase activity
(SteadyGlo, Promega).
Neutralization assay
Purified IgG of brNAbs 2F5 [63], 4E10 [64] and IgGb12
[95,96] were obtained from Polymun Scientific, while the
HR2 peptide analogue, C34 [43], was purchased from
Genscript. Neutralization assays were conducted using
TZM-bl cells (obtained from J. C. Kappes, X. Wu and
Tranzyme Inc., NIH AIDS Research and Reference Re-
agent Program [97-99]), a HeLa cell line expressing CD4
and CCR5 and harbouring integrated copies of the lucifer-
ase and β-galactosidase genes under control of the HIV-1
promoter. Virus stocks produced by pAD8-transfected
293T cells and determined to give ~1.5 × 106 relative light
units (RLU) following infection of TZM-bl cells, were
mixed with an equal volume of serially diluted IgG or C34
peptide and incubated for 1 h at 37°C. One hundred μl of
the virus-IgG mixtures was then added to TZM-bl cells
(104 cells in 100 μl per well of a 96-well tissue culture
plate) and incubated for 2 days prior to lysis and assay for
luciferase activity (Promega, Madison, WI). For experi-
ments with the CCR5 antagonist maraviroc (NIH AIDS
Research and Reference Reagent Program [100]), the cells
were preincubated for 1 h at 37°C with the drug prior to
incubation with virus for 48 h. Neutralizing activities were
measured in triplicate and reported as the average percent
luciferase activity.
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